**Part 5**

**Aging and Endocrinology** 

176 Basic and Clinical Endocrinology Up-to-Date

Vella, A. and Service F. J. (2007). "Incretin hypersecretion in post-gastric bypass

Vezzosi, D., Bennet A., et al. (2003). "Insulin levels measured with an insulin-specific assay in

Vezzosi, D., Bennet A., et al. (2005). "Octreotide in insulinoma patients: efficacy on

Vezzosi, D., Bennet A., et al. (2008). "Short- and long-term somatostatin analogue treatment in

Wiesli, P., Brändle M., et al. (2004a). "Insulin determination by specific and unspecific

Witteles, R. M., Straus I. F., et al. (2001). "Adult-onset nesidioblastosis causing hypoglycemia:

Yanai, H., Yoshida H., et al. (2008). "Severe hypoglycemia in a patient with anorexia nervosa."

Yang, Y. and Hua X. (2007). "In search of tumor suppressing functions of menin." *Molecular and* 

Yao, J.C., Shah M.H., et al. (2011). Everolimus for advanced pancreatic neuroendocrine tumors.

Yoshioka, R., Saiura A., et al. (2010). "Risk factors for clinical pancreatic fistula after distal

Zhao, Y. P., Zhan H. X., et al. (2011). "Surgical management of patients with insulinomas: Result of 292 cases in a single institution." *Journal of Surgical Oncology* 103(2): 169-174. Zitzmann, S., Reimann I. R., et al. (2002). "Severe hypoglycemia in an elderly patient treated

pancreatectomy: analysis of consecutive 100 patients." *World Journal of Surgery* 34(1):

with metformin." *International Journal of Clinical Pharmacology and Therapeutics* 40(3):

venous sampling test." *European Journal of Endocrinology* 151(1): 123-126. Wiesli, P., Schmid C., et al. (2004b). "Hypoglycemia in response to glucose and glucagon in

properties." *Journal of Endocrinological Investigation* 27(9): 832-838.

*Metabolism* 92(12): 4563-4565.

*Journal of Endocrinology* 157(1): 75-83.

*Eating and Weight Disorders* 13(1): e1-3.

*Cellular Endocrinology* 265-266: 34-41.

*New England Journal of Medicine* 364(6): 514-523

*Endocrinology* 68(6): 904-911.

136(6): 656-663.

121-125.

108-110.

*European Journal of Endocrinology* 149(5): 413-419.

hypoglycemia--primary problem or red herring?" *Journal of Clinical Endocrinology and* 

patients with fasting hypoglycaemia related to endogenous hyperinsulinism."

hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies." *European Journal of Endocrinology* 152(5): 757-767. Vezzosi, D., Bennet A., et al. (2007). "Insulin, C-peptide and proinsulin for the biochemical

diagnosis of hypoglycaemia related to endogenous hyperinsulinism." *European* 

patients with hypoglycaemia related to endogenous hyperinsulinism." *Clinical* 

immunoassays in patients with insulinoma evaluated by the arterial stimulation and

insulinoma patients with a negative prolonged fast: functional and morphological

an important clinical entity and continuing treatment dilemma." *Archives of Surgery* 

**9** 

Xing Jia Wang

*USA* 

**Natural Flavonoids in StAR Gene** 

**Biosynthesis in Leydig Cell Aging** 

It is well known that blood testosterone level declines during the course of male aging (Feldman et al., 2002; Harman et al., 2001), a phenomena that is associated with the decreases in bone density, muscle mass and strength, sexual function and other physiological parameters (Kaufman & Vermeulen, 2005; Matsumoto, 2002; Vermeulen, 2000). Previous studies reported that serum testosterone concentrations were lower in the male patients with Alzheimer's disease in comparison to non-demented and age-matched men (Hogervorst et al., 2001; Moffat et al., 2004). Further studies observed that supplementation with testosterone in rats reduced β-amyloid peptide and hyperphosphorylation of τ-protein, two biomarkers of the disease (Gouras et al., 2000; Papasozomenos & Shanavas, 2002; Ramsden et al., 2003). The studies suggest that low blood testosterone is a possible risk factor for the development of Alzheimer's disease (Rosario & Pike, 2008). The decline in blood testosterone is a progressive process in male aging. Several longitudinal studies on the blood testosterone of aging males indicated that the incidence of hypogonadism increased with age (Feldman et al., 2002; Harman et al., 2001). In addition, many pathological and stressrelated factors may accelerate this process. Therefore, delaying the decline in blood testosterone is clinically significant for the health of aging males suffering from

For delaying the decline in testosterone, understanding the mechanisms responsible for the decline is important. The studies in the last decades reported multiple factors and alterations in aging process that affect the levels of blood testosterone (Wang & Stocco, 2005). The studies further indicated that the primary reason for the decline is the decrease in testosterone biosynthesis during male aging (Chen et al., 1994). Testosterone is principally synthesized in testicular Leydig cells from the substrate cholesterol and released into the blood circulation (Miller, 1988). The rate-limiting step in testosterone biosynthesis is the transfer of cholesterol to the mitochondrial inner membrane to initiate the steroidogenic process in Leydig cells (Stocco & Clark, 1996). This step is regulated by the steroidogenic acute regulatory (StAR) protein, a critical factor in steroid hormone biosynthesis that controls the cholesterol transfer to the mitochondrial inner membrane (Clark et al., 1994; Lin et al., 1995; Wang et al., 1998). However, StAR protein also declines in Leydig cell aging and

**1. Introduction** 

hypogonadism.

**Expression and Testosterone** 

*Garrison Institute on Aging, Department of Neurology* 

 *Texas Tech University Health Sciences Center* 
